key: cord-1044059-rhouelxm
authors: Akilesh, Shreeram; Nast, Cynthia C.; Yamashita, Michifumi; Henriksen, Kammi; Charu, Vivek; Troxell, Megan L.; Kambham, Neeraja; Bracamonte, Erika; Houghton, Donald; Ahmed, Naila I.; Chong, Chyi Chyi; Thajudeen, Bijin; Rehman, Shehzad; Khoury, Firas; Zuckerman, Jonathan E.; Gitomer, Jeremy; Raguram, Parthassarathy C.; Mujeeb, Shanza; Schwarze, Ulrike; Shannon, M. Brendan; De Castro, Iris; Alpers, Charles E.; Najafian, Behzad; Nicosia, Roberto F.; Andeen, Nicole K.; Smith, Kelly D.
title: Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria
date: 2020-10-10
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2020.10.001
sha: 3a78005bd38976a33f1d52ce4cae616eb9884903
doc_id: 1044059
cord_uid: rhouelxm

RATIONALE AND OBJECTIVE: Kidney biopsy data inform us about pathologic processes associated with SARS CoV-2 infection. We conducted a multi-center evaluation of kidney biopsy findings in living patients to identify various kidney disease pathology in patients with COVID-19 and their association with SARS-CoV-2 infection. STUDY DESIGN: Case series. SETTING AND PARTICIPANTS: We identified 14 native and 3 transplant kidney biopsies performed for-cause in patients with documented recent or concurrent COVID-19 infection treated at 7 large hospital systems in the United States. OBSERVATIONS: Males and females were equally represented in our study cohort, with a higher proportion of Black (n=8) and Hispanic (n=5) patients. All 17 patients had RT-PCR confirmed COVID-19 infection, but only 3 presented with severe COVID-19 symptoms. Acute kidney injury (AKI; n=15) and proteinuria (n=11) were the most common indications for biopsy and these symptoms developed concurrently or within 1 week of COVID-19 symptoms in all patients. Acute tubular injury (n=14), collapsing glomerulopathy (n=7) and endothelial injury/thrombotic microangiopathy (n=6) were the most common histologic findings. Two of the three transplant patients developed active antibody-mediated rejection weeks after COVID-19 infection. Eight patients required dialysis, but others improved with conservative management. LIMITATIONS: Small study size and short clinical follow up. CONCLUSIONS: Cases of even symptomatically mild COVID-19 infection were accompanied by AKI and/or heavy proteinuria that prompted a diagnostic kidney biopsy. While acute tubular injury was seen among the majority of them, uncommon pathology such as collapsing glomerulopathy and acute endothelial injury were detected, and most of these patients progressed to irreversible kidney injury and dialysis.

Observations: Males and females were equally represented in our study cohort, with a higher proportion of Black (n=8) and Hispanic (n=5) patients. All 17 patients had RT-PCR confirmed COVID-19 infection, but only 3 presented with severe COVID-19 symptoms. Acute kidney injury (AKI; n=15) and proteinuria (n=11) were the most common indications for biopsy and these symptoms developed concurrently or within 1 week of COVID-19 symptoms in all patients. Acute tubular injury (n=14), collapsing glomerulopathy (n=7) and endothelial injury/thrombotic microangiopathy (n=6) were the most common histologic findings. Two of the three transplant patients developed active antibody-mediated rejection weeks after infection. Eight patients required dialysis, but others improved with conservative management.

Limitations: Small study size and short clinical follow up.

Conclusions: Cases of even symptomatically mild COVID-19 infection were accompanied by AKI and/or heavy proteinuria that prompted a diagnostic kidney biopsy. While acute tubular injury was seen among the majority of them, uncommon pathology such as collapsing glomerulopathy and acute endothelial injury were detected, and most of these patients progressed to irreversible kidney injury and dialysis.

J o u r n a l P r e -p r o o f Introduction Since its identification, SARS-CoV-2 infection and its resulting disease, COVID-19, has grown into a worldwide pandemic with devastating medical and financial impacts. Though the primary targets of injury are the lungs and airways, cardiac and renal involvement are common and portend a worse prognosis. [1] [2] [3] [4] Pre-existing renal disease or diseases known to contribute to renal impairment such as hypertension and diabetes are risk factors for an aggressive clinical course. 2, [5] [6] [7] [8] De novo renal impairment in SARS-CoV-2 infected patients manifests as acute kidney injury (AKI), proteinuria, and hematuria. 3, 9 Various mechanisms have been proposed for kidney injury, including ischemia related to severe pulmonary injury, high levels of circulating pro-inflammatory cytokines ("cytokine storm") and bradykinin, and possible direct infection of the renal parenchyma by SARS-CoV-2. However, very few patients with COVID-19 undergo kidney biopsy to identify the pathologic processes affecting the kidney, since management of pulmonary disease and infection precautions often take precedence. Therefore, we aggregated kidney biopsies performed on patients with documented COVID-19 from multiple large medical centers in the United States to identify clinicopathologic correlations of renal impairment.

After study conception by SA, NKA and KDS, a request for collaboration and case contribution was sent to renal pathologists at large medical centers. Once cases were identified at each institution, biopsy and electronic health record review were performed locally as human subjects cases; STUDY00017467), Cedars-Sinai Medical Center (3 cases; STUDY00000903); University 

For case 1, genetic testing was performed at GeneDx Laboratories (Gaithersburg, MD). For case 6, genomic DNA was isolated from EDTA anticoagulated blood with the PureLink Genomic DNA kit (ThermoFisher Scientific). The region of APOL1 containing the G1 and G2 risk alleles was amplified by PCR, and the product sequenced by automated sequencing in 2 reactions. Sequence data were analyzed by the most recent version of the Mutation Surveyor software (SoftGenetics).

For SARS-CoV-2 nucleocapsid protein, formalin-fixed paraffin-embedded (FFPE) tissue sections were immunohistochemically stained with an antibody to SARS-CoV nucleocapsid protein (Catalog #40143-T62, Sinobiological, Wayne, PA) at 1:2000 dilution on Leica Bond III instruments after 20 min antigen retrieval with epitope retrieval 2, followed by Leica Bond Polymer Refine detection chemistry. For RNA in situ hybridization, FFPE was stained with SARS-CoV2 probe (ACD Bio RNAscope® Probe -V-nCoV2019-S, cat# 848568) on Leica platform with 3,3'-diaminobenzidine (DAB), protease retrieval, and hybridization per manufacturer protocols.

J o u r n a l P r e -p r o o f We identified 17 patients (8 male, 9 female) with RT-PCR documented COVID-19 infection.

The clinical characteristics of our cohort are summarized in Table 1 . Additional information on baseline laboratory and clinical parameters, medication usage and pathologic findings are detailed in Table S1 . The median age of our patients was 54 years (range 34-77 years). Our cohort was predominantly Black (n= 8, 47%) and Hispanic (n= 5, 29%). Most patients had only mild COVID-19 related symptoms such as upper respiratory tract infection, cough, fatigue or low-grade fevers, though at least three required hospitalization for hypoxic pulmonary failure.

Fourteen patients presented with native kidney impairment while three presented with allograft kidney impairment. AKI (n=15; median serum creatinine 5.5 mg/dL and range 0.7-12 mg/dL) and heavy proteinuria (n=11) were the most common indications for biopsy. Hypertension was almost uniformly present in our patient cohort, while diabetes and obesity were less frequent.

The most severe AKI presentations were in the six patients who presented with severe hypertension often >150/100 mmHg (cases 6-11). Four of these (cases 8-11) had characteristic laboratory features of thrombotic microangiopathy (TMA), including anemia, thrombocytopenia, elevated serum lactate dehydrogenase, and low haptoglobin with normal ADAMTS13 activity.

Three of 4 had additional conditions which may have contributed to TMA, including cytotoxic and/or illicit drug use and poorly controlled hypertension. The first of these patients (case 8) presented with mental status changes and intracranial hemorrhage and ultrasound imaging revealed atrophic appearing kidneys suggesting long-standing poorly controlled blood pressure.

The second patient (case 9) had mental status changes, normal complement levels, and had previously been treated with gemcitabine for adenocarcinoma. She presented with oliguric AKI and nephrotic range proteinuria. The third patient (case 10) had evidence of activation of the alternative complement pathway (low serum C3 with normal C4), which has been reported in J o u r n a l P r e -p r o o f patients with COVID-19. 10 The fourth patient initially presented only with fatigue (case 11) and 2 days later he was diagnosed with COVID-19. At that time his serum creatinine was 1.62 mg/dL. 23 days later, his pulmonary symptoms had worsened, and he was admitted for pulmonary edema and high blood pressure (165/87 mmHg). His social history was significant for active cocaine use and he was being treated with gemcitabine, vinorelbine, and doxorubicin for There was often a delay between onset of kidney symptoms/COVID-19 diagnosis and performance of the kidney biopsy. Reasons for this delay were varied but included abundance of caution with infectious precautions at the onset of the pandemic (cases 5, 9, 16, 17) , hemodynamic instability (cases 1, 8), observation during initial improvement which was followed by further decline (cases 2, 3, 11) and scheduling hurdles (cases 12, 15). These delays were not unique to a given institution and are likely comparable to biopsy-scheduling practices at large referral centers nation-wide.

The findings on kidney biopsy are summarized in Table 2 with clinical follow up summarized in Table 3 . patients assumed the form of collapsing glomerulopathy (Fig 1B-D) . One of these patients (case 6) was diagnosed with collapsing glomerulopathy three years prior and had been clinically stable with a baseline serum creatinine of 2 mg/dL and a urine protein/creatinine ratio of 2 g/g. During the course of his COVID-19 infection, his serum creatinine rose to 12 mg/dL with a 11.4 g/g protein/creatinine ratio. All 11 FSGS patients, as well as the patient diagnosed with minimal change disease (case 5) presented with >3 g/g proteinuria (uPCR), which correlated with diffuse podocyte foot process effacement by electron microscopy. Two patients were tested and found to have high-risk APOL1 genotypes (cases 1 & 6).

Six patients (cases 6-11) demonstrated evidence of acute endothelial cell injury by light and/or electron microscopy including all 4 clinically suspected of having acute TMA (cases [8] [9] [10] [11] . This ranged from mild injury with ultrastructural evidence of glomerular subendothelial space widening and/or loss of endothelial cell fenestrae to severe injury manifest by endothelial cell swelling and fibrin thrombi within glomerular hilar arterioles and small arteries evident by light microscopy (Fig 1D-F) . Peritubular capillary thrombi were not seen in any of the cases in our cohort. Microangiopathic features were seen in the setting of collapsing glomerulopathy (cases 6-9), and/or with prominent arteriolar involvement in the background of severe 

Using electron microscopy, earlier reports have suggested direct viral infection of the kidney. 11, 12 However, unambiguous identification of viral particles in autopsy tissue is difficult due to postmortem degradation artifacts. We therefore reasoned that 3 criteria were required to establish direct viral infection of tissues: 1) viral particles of expected size (80-140nm) with the electron dense dots of the nucleocapsid cores and, when visible, spikes facing the lumen of vacuoles; 13, 14 2) viral particles present in the appropriate subcellular compartment (e.g. intracisternal spaces of the endoplasmic reticulum and Golgi, cytoplasmic vesicles, and extracellular spaces) compatible with known viral replication and trafficking pathways; 15 

There were often several weeks of delay between kidney impairment onset and the biopsy procedure, and most patients were SARS-CoV-2 PCR negative at the time of biopsy ( Table 3) .

Since most patients had only mild COVID-19 related symptoms, treatment focused on managing their kidney disease diagnosed on biopsy, usually with diuretics and blood pressure control. This resulted in improvement in 7/12 patients; at least eight patients required dialysis including 6/7 patients diagnosed with collapsing glomerulopathy, and all 6 with presenting with suspected or clinically confirmed TMA. Seven patients remain on dialysis at the time of this writing.

In our cohort of COVID-19 patients, the most frequent indications for biopsy was an acute rise in the serum creatinine (15/17, 88%) , new onset of proteinuria (11/17, 65%) and hematuria (4/17, 24%). All patients' renal dysfunction presented concurrently with or within one week of RT-PCR confirmed SARS-CoV-2 infection, and most had only mild COVID-19 symptoms.

However, there was often several weeks delay between onset of COVID-19 symptoms or confirmed positive RT-PCR test and the kidney biopsy procedure (Table 3) . Therefore, most biopsies were performed after individuals were PCR-negative and considered to be of low J o u r n a l P r e -p r o o f infection risk. Histologically, acute tubular injury was seen in the majority (14/17, 82%) of our biopsy cohort. The most striking finding is the high incidence of collapsing glomerulopathy (7/17, 41%) , which has been reported by multiple groups in association with SARS-CoV-2 infection. [16] [17] [18] [19] [20] The mechanism driving this acute glomerular injury process is possibly related to interferon production, a known trigger of collapsing glomerulopathy. [21] [22] [23] It is less likely that direct podocyte infection is an etiologic factor as the 3/4 patients who were negative for virus by IHC and/or in situ hybridization had podocytopathies (1 each FSGS, collapsing glomerulopathy and minimal change disease). We were able to genotype one Black patient (case 1) who was found to carry the high risk G1/G1 APOL1 genotype. While we did not genotype the other patients in our cohort, 6/7 patients with collapsing glomerulopathy were Black, consistent with other reports demonstrating a strong association between collapsing glomerulopathy in the setting of SARS-CoV-2 infection with high-risk APOL1 genotypes, 17,19,24 a susceptibility that parallels its incidence in HIV-infected patients. 24, 25 The last patient with collapsing glomerulopathy (case 6) was a Hispanic patient from Mexico who was also found to have a high risk G2/G2 APOL1 genotype even though the prevalence of homozygous high-risk APOL1 genotypes in mainland Hispanics is 0.1%. 26 Acute TMA and more subtle ultrastructural evidence of acute endothelial cell injury were also common findings in our cohort (6/17, 35%). 4/6 of these patients had underlying hypertension, and two had prior or ongoing treatment with gemcitabine (one of which also used cocaine), and thus had potential additional drivers for TMA besides SARS-CoV-2 infection.

Four patients' biopsies with TMA/endothelial injury also demonstrated collapsing glomerulopathy, and two allograft biopsies showed endothelial cell injury in the setting of antibody-mediated rejection. Interestingly, TMA has been associated with collapsing J o u r n a l P r e -p r o o f glomerulopathy, [27] [28] [29] [30] and endothelial injury is the most common manifestation of antibodymediated rejection. 31, 32 Thus, the frequent finding of acute TMA and more subtle ultrastructural evidence of acute endothelial cell injury appears to be the manifestation of the underlying disease processes in our cohort. Endothelial injury and dysfunction are emerging mechanisms in severe COVID-19, and other groups have suggested that endothelial injury may be a manifestation of SARS-CoV-2 infection and contribute to kidney injury. 11, 33, 34 Our series demonstrates that a broad clinical and pathologic spectrum of acute endothelial injury may exist even in the absence of significant COVID-19-related respiratory symptoms, and some of these changes can be attributed to co-existing diseases. It is possible that SARS-CoV-2 infection may exacerbate clinical situations predisposing to endothelial injury such as hypertension, antibody-mediated rejection, pro-thrombotic states and endothelial toxins. Additional data will be helpful to determine whether this is an important clinical consideration.

To our knowledge, this is the first report of infection-related glomerulonephritis (case 12) in the setting of COVID-19. Infection-related glomerulonephritis is most commonly associated with bacterial infections but has been seen in association with viral infections, such as Parvovirus B19 and influenza virus H1N1. [35] [36] [37] Our patient manifested kidney symptoms 19 days after testing positive for SARS-CoV-2, indicating that the timing of glomerulonephritis fits with the pathogenesis of post-infectious glomerulonephritis. However, this patient also had nodular diabetic nephropathy and a concurrent urinary tract infection (UTI), and it is possible that the UTI was a cause of, or contributor to, the infection-related glomerulonephritis. We also report a case of minimal change disease in a one patient (case 5). In contrast to the Black patient with a high-risk (G1/G1) APOL1 genotype who presented with minimal change disease in a recent report, 20 our patient is White. However, it is well appreciated that minimal change disease may Emergence of de novo donor specific antibodies has also been recently been reported in a pediatric heart transplant recipient who was infected with SARS-CoV-2. 44 Kidney allograft recipients may therefore be at increased risk for developing de novo DSAs and active antibodymediated rejection after SARS-CoV-2 infection.

Direct viral infection of the kidney by SARS-CoV-2 has been proposed as a possible mechanism of kidney injury and is an attractive concept since both podocytes and proximal tubular epithelial cells express high levels of the ACE2 entry receptor. 11, [45] [46] [47] We could not establish direct kidney infection by SARS-CoV-2 in our cohort, though a caveat is that there was often a several week delay between diagnosis of COVID-19 and performing the kidney biopsy.

We note that the temporal relationship between onset of kidney impairment, COVID-19 symptoms and diagnostic biopsy has not been clearly reported in the previous studies to date. 10, 16, 17, 20, 48 Detectable SARS-CoV-2 may wane quickly with time after the onset of infection similar to SARS-CoV. 49, 50 Therefore, these delays meant that most patients in our cohort may have cleared virus from their kidney and were therefore RT-PCR negative by nasopharyngeal J o u r n a l P r e -p r o o f swab at the time of biopsy. Even with this caveat, most recent biopsy and autopsy case series have concluded that there is no significant SARS-CoV-2 infection of the kidney, 16, 20, 24, 48, [51] [52] [53] which is in contrast to the possibility of direct infection that was reported in two earlier studies. 11, 45 Therefore, our study adds to the accumulating evidence that direct and persistent infection of the kidney by SARS-CoV-2 does not appear to play a significant role in kidney disease in most COVID-19 patients.

Many studies have relied solely on electron microscopy to establish direct viral infection of tissues. However, without orthogonal validation and rigorous controls this approach is problematic since there are many ultrastructural mimics of viral particles. 51, [54] [55] [56] Even in the lung, using validated immunohistochemistry and RNA in situ hybridization, very few cells appear to contain detectable virus. 45, 52 If direct viral infection of the kidney occurs, the lower viral load compared to lung tissue would make ultrastructural identification of exceedingly rare SARS-CoV-2 particles in the kidney improbable amongst the ubiquitous viral mimics. 45 In contrast to the patients in two autopsy series or those in a recent biopsy series, 11, 20, 48, 53 the majority of patients in our cohort had only mild COVID-19 symptoms while presenting with acute kidney injury, heavy proteinuria, and/or severe hypertension. Some diseases detected in our patient cohort may represent diagnoses coincident with COVID-19 disease. On the other hand, the high incidence of typically rare disease processes such as collapsing glomerulopathy and thrombotic microangiopathy raises the possibility of SARS-CoV-2 infection contributed to these injuries, even in the absence of direct infection of the renal parenchyma. Given that the majority of SARS-CoV-2 infected patients exhibit only mild symptoms such as those in our cohort, the incidence of acute kidney injury and proteinuria may rise as the pandemic progresses, and J o u r n a l P r e -p r o o f disproportionately impact more vulnerable populations with pre-existing risk factors for kidney disease or high-risk APOL1 genotypes.

Table S1: Additional information on cases. 

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Factors associated with COVID-19-related death using OpenSAFELY

Acute kidney injury in patients hospitalized with COVID-19

Kidney disease is associated with in-hospital death of patients with COVID-19

Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Presentation and Outcomes of Patients with ESKD and COVID-19

The Novel Coronavirus 2019 epidemic and kidneys

Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Visualization of putative coronavirus in kidney

Caution in Identifying Coronaviruses by Electron Microscopy

Ultrastructural Characterization of SARS Coronavirus

Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19)

Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection

Tubuloreticular inclusions in COVID-19-related collapsing glomerulopathy

COVID-19-Associated Collapsing Focal Segmental Glomerulosclerosis: A Report of 2 Cases

Kidney Biopsy Findings in Patients with COVID-19

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection

APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI)

AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype

APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans

African ancestry-specific alleles and kidney disease risk in hispanics/latinos

Glomerulopathy and arteriolopathy in congenital nephrotic syndrome: Light, electron, and fluorescence microscopy studies

De novo collapsing glomerulopathy in renal allografts

Collapsing glomerulopathy in renal allografts: A morphological pattern with diverse clinicopathologic associations

Zonal distribution of glomerular collapse in renal allografts: Possible role of vascular changes

Talking back: the podocytes and endothelial cells duke it out

Review: The transcripts associated with organ allograft rejection

COVID-19: the vasculature unleashed

Thrombotic microangiopathy in a patient with COVID-19

Post-infectious acute glomerulonephritis with podocytopathy induced by parvovirus B19 infection

Postinfectious glomerulonephritis secondary to erythrovirus B19 (parvovirus B19): Case report and review of the literature

A case of post-infectious glomerulonephritis following infection with influenza A subtype H1N1

Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus

Spontaneous remission of adult-onset minimal change nephrotic syndrome associated with influenza B infection: A case report

Minimal change glomerulonephritis with reversible proteinuria during interferon α2a therapy for chronic myeloid leukemia

Treatment with IFN-α,-β,or-γ is associated with collapsing focal segmental glomerulosclerosis

Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms

Allo-HLA reactivity of virus-specific memory T cells is common

COVID-19 in a pediatric heart transplant recipient: Emergence of donor-specific antibodies

Multiorgan and Renal Tropism of SARS-CoV-2

SARS-CoV-2 Receptor Networks in Diabetic Kidney Disease, BK-Virus Nephropathy and COVID-19 Associated Acute Kidney Injury

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings

Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies

Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS

Appearances can be deceiving -viral-like inclusions in COVID-19 negative renal biopsies by electron microscopy

Detection of SARS-CoV-2 in formalin-fixed paraffin-embedded tissue sections using commercially available reagents

Lab Investig

Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19

Electron microscopic investigations in COVID-19: not all crowns are coronas

Am I a coronavirus?

Electron microscopy of SARS-CoV-2: a challenging task

FPE=Podocyte foot process effacement. TRIs= tubuloreticular inclusions. IgAN= IgA nephropathy. ISH= in situ hybridization. Ab=antibody. Mod=moderate Abbreviations: NA=not available. PCR=polymerase chain reaction. ATN=acute tubular injury. FSGS=focal segmental glomerulosclerosis. TMA=thrombotic microangiopathy. GN=glomerulonephritis. EM=electron microscopy. IgAN=IgA nephropathy. TIN=tubulointersitital nephritis. SCr= serum creatinine in mg/dL

J o u r n a l P r e -p r o o f